PATHOLOGICAL CHEMOTHERAPY RESPONSE SCORE PREDICTS SURVIVAL IN PATIENTS WITH ADVANCED OVARIAN CANCER RECEIVING NEOADJUVANT CHEMOTHERAPY: AN INDIVIDUAL PATIENT META-ANALYSIS

Paul Cohen, Steffen Bohm, Aime Powell, Tarek Meniawy, Colin Stewart, Max Bulsara, C. Blake Gilks, Naveena Singh

Research output: Contribution to journalConference article

Abstract

Background and Aims: The chemotherapy response score (CRS) is recommended for uniform recording of histological tumor response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC)1. CRS reproducibly stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response2. Single-center studies have shown an association between CRS and progression-free survival (PFS) but not overall survival (OS)3-6. Our objective was to perform an individual patient data (IPD) meta-analysis for further prognostic validation. Methods: Data from 14 centers in 10 countries were analysed. Eligibility criteria were: stage III/IV HGSC, 3/4 NACT cycles, locally determined CRS, minimum 6-month follow-up, known survival outcomes. Meta-analysis techniques for IPD with random effects were used to derive combined odds ratios (ORs). Results: Data from 813 patients fulfilled eligibility criteria. 486 (59.8%) and 327 (40.2%) patients had stages III and IV disease respectively. Median follow up was 28 months. Median OS was 28.0 months. 621 (76%) and 362 (45%) patients relapsed and/or died. 549 patients (67.5%) showed CRS1/2 and 264 (32.5%) showed CRS3. Adjusting for age, stage and residual disease, PFS was significantly improved (21.9 vs. 14.5 months, OR 0.5, 95% CI 0.45–0.67, p =
Original languageEnglish
Pages (from-to)1-1258
Number of pages1258
JournalInternational Journal of Gynecological Cancer
Volume28
Issue numberS2
DOIs
Publication statusPublished - Sep 2018
Event 17th Biennial Meeting of the International Gynecologic Cancer Society - Kyoto, Japan
Duration: 14 Sep 201816 Sep 2018

    Fingerprint

Cite this